 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | B38-CAP / Kafrelsheikh University
Journal: Integrated computational approach towards identification of HSPG and ACE2 mimicking moieties for SARS-CoV-2 inhibition. (Pubmed Central) - Oct 25, 2022
Further, the binding stability and compactness of these moieties with SARS-CoV-2 were analyzed through molecular dynamics (MD) simulations, and the results indicated that these moieties form well-stable complexes with the RBD of spike proteins. The identified moieties could be conjugated to the surfaces of non-toxic nanoparticles to provide multiple interactions to efficiently shield SARS-CoV-2, and inhibit viral entry to the host cells.
- | B38-CAP / Kafrelsheikh University
Journal: ACE2-like enzyme B38-CAP suppresses abdominal sepsis and severe acute lung injury. (Pubmed Central) - Jul 30, 2022
B38-CAP suppressed the pathologies of lung inflammation, improved lung dysfunction and downregulated elevated cytokine mRNA levels in the mice with acute lung injury. Thus, systemic treatment with an ACE2-like enzyme might be a potential therapeutic strategy for the patients with severe sepsis or ARDS.
- | B38-CAP / Kafrelsheikh University
Journal: Structural insights revealed by crystal structure of B38-CAP, an isoenzyme of carboxypeptidase ACE2, the receptor of SARS-CoV-2. (Pubmed Central) - Apr 27, 2022
Further structural analysis revealed the structural conservatism feature among M32 family, particularly the catalytic core and moreover lead us to hypothesize that conformational flexibility might play an pivotal role in the catalysis of B38-CAP and ACE2. The work provided here presents key features of the M32 family carboxypeptidase and provides structural basis for further development of B38-CAP-based anti-SARS-CoV-2 drugs.
- | B38-CAP / Kafrelsheikh University
Journal: ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. (Pubmed Central) - Dec 16, 2021
In SARS-CoV-2-infected hamsters or human ACE2 transgenic mice, B38-CAP significantly improves lung edema and pathologies of lung injury. These results provide the first in vivo evidence that increasing ACE2-like enzymatic activity is a potential therapeutic strategy to alleviate lung pathologies in COVID-19 patients.
- | B38-CAP / Kafrelsheikh University, isotretinoin / Kafrelsheikh University
Trial completion date, Trial primary completion date: Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications (clinicaltrials.gov) - Jun 9, 2021
P1, N=24, Not yet recruiting, Sponsor: Kafrelsheikh University
These results provide the first in vivo evidence that increasing ACE2-like enzymatic activity is a potential therapeutic strategy to alleviate lung pathologies in COVID-19 patients. Trial completion date: Dec 2020 --> Oct 2021 | Trial primary completion date: Nov 2020 --> Aug 2021
- | B38-CAP / Kafrelsheikh University
Trial completion date, Trial primary completion date: Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2 (clinicaltrials.gov) - Jun 9, 2021
P1, N=24, Not yet recruiting, Sponsor: Kafrelsheikh University
Trial completion date: Dec 2020 --> Oct 2021 | Trial primary completion date: Nov 2020 --> Aug 2021 Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: May 2021 --> Aug 2021
- | B38-CAP / Kafrelsheikh University
Trial completion date, Trial initiation date, Trial primary completion date: Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2 (clinicaltrials.gov) - Apr 22, 2021
P1, N=24, Not yet recruiting, Sponsor: Kafrelsheikh University
Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: May 2021 --> Aug 2021 Trial completion date: Oct 2020 --> Jun 2021 | Initiation date: Sep 2020 --> Apr 2021 | Trial primary completion date: Sep 2020 --> May 2021
- | B38-CAP / Kafrelsheikh University, isotretinoin / Kafrelsheikh University
Trial completion date, Trial primary completion date: Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications (clinicaltrials.gov) - Jun 7, 2020
P1, N=24, Not yet recruiting, Sponsor: Kafrelsheikh University
Trial completion date: Oct 2020 --> Jun 2021 | Initiation date: Sep 2020 --> Apr 2021 | Trial primary completion date: Sep 2020 --> May 2021 Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Jul 2020 --> Nov 2020
- | B38-CAP / Kafrelsheikh University, isotretinoin / Kafrelsheikh University
New P1 trial: Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications (clinicaltrials.gov) - May 10, 2020
P1, N=24, Not yet recruiting, Sponsor: Kafrelsheikh University
- | B38-CAP / Kafrelsheikh University
New P1 trial: Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2 (clinicaltrials.gov) - May 4, 2020
P1, N=24, Not yet recruiting, Sponsor: Kafrelsheikh University